Pure Bioscience, Inc. (OTCMKTS:PURE)’s share price passed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $0.40 and traded as high as $0.35. Pure Bioscience shares last traded at $0.32, with a volume of 87,412 shares changing hands.
The stock’s 50-day simple moving average is $0.40.
In related news, Director Ivan Chen acquired 100,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 9th. The stock was purchased at an average cost of $0.35 per share, for a total transaction of $35,000.00. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 44.18% of the company’s stock.
PURE Bioscience, Inc develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. It manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection and formulates with other compounds.
Featured Story: Does a trade war provide a risk to the global economy?
Receive News & Ratings for Pure Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pure Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.